SLC5A2 and type 2 diabetes mellitus: Despite receiving standard-of-care treatment with optimal doses of an RAS blocker and the concomitant use of an SGLT-2 inhibitor, patients with T2D and CKD remain at a high risk of adverse cardiorenal outcomes.